BioCentury
ARTICLE | Clinical News

Aronex starts Phase II with Annamycin

March 28, 2000 8:00 AM UTC

ARNX started a U.S. Phase II open label trial to assess safety and efficacy of Annamycin, a liposomal anthracycline, to treat refractory breast cancer in patients overexpressing P-glycoprotein in tumo...